Author

S. Periasamy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 6 Organism:mouse· 4 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. Bukreyev· 6 shared P.-Y. Shi· 3 shared A. R. Shiakolas· 2 shared D. Wrapp· 2 shared E. Zaslavsky· 2 shared I. S. Georgiev· 2 shared J. E. Crowe· 2 shared J. S. McLellan· 2 shared

Activity by Year

2021-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

A. Bukreyev

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Multiple layers of innate immune response antagonism of SARS-CoV-2

F. Zhou, S. Periasamy, N. Jackson, W. S. Cheng, R. Soto Acosta, P. Ilinykh, C. Ye, S. Chauhan, G. Nudelman, E. Zaslavsky, S. Widen, L. Martinez-Sobrido, S. Sealfon, A. Bukreyev

This study generates twelve SARS-CoV-2 viruses with mutations in individual proteins and shows that many have interferon-antagonizing activity and immunosuppressive effects in human cells and mice, with NSP1 and NSP15 having the greatest impact.

bioRxiv · Jan 29, 2024 · PreprintMicrobiology

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions

Y. Liu, X. Zhang, J. Liu, H. Xia, J. Zou, A. E. Muruato, S. Periasamy, J. A. Plante, N. E. Bopp, C. Kurhade, A. Bukreyev, P. Ren, T. Wang, V. D. Menachery, K. S. Plante, , P.-Y. Shi

This paper describes a live-attenuated SARS-CoV-2 vaccine candidate with deleted ORFs that shows reduced replication and attenuation in animal models, and reports its protective efficacy against wild-type virus challenge.

bioRxiv · Feb 14, 2022Microbiology

Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking

A. R. Shiakolas, N. Johnson, K. J. Kramer, N. Suryadevara, D. Wrapp, S. Periasamy, K. A. Pilewski, N. Raju, R. Nargi, R. E. Sutton, L. Walker, I. Setliff, J. E. Crowe, A. Bukreyev, R. H. Carnahan, , I. S. Georgiev

This study demonstrates that integrating ligand blocking into LIBRA-seq improves the efficiency of identifying potent SARS-CoV-2 neutralizing antibodies.

bioRxiv · Jun 2, 2021 · PreprintImmunology

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition

K. J. Kramer, N. V. Johnson, A. R. Shiakolas, N. Suryadevara, S. Periasamy, N. Raju, J. K. Williams, D. Wrapp, S. J. Zost, C. M. Holt, C.-L. Hsieh, R. E. Sutton, A. Paulo, E. Davidson, B. J. Doranz, , I. S. Georgiev

This study identifies a potent SARS-CoV-2 antibody, 54042-4, that neutralizes variants of concern and has a unique epitope and genetic structure.

bioRxiv · May 16, 2021Immunology

A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

D. C. Malherbe, D. Kurup, C. Wirblich, A. J. Ronk, C. Mire, N. Kuzmina, N. Shaik, S. Periasamy, M. A. Hyde, J. M. Williams, P.-Y. Shi, M. J. Schnell, A. Bukreyev

A single dose of the VSV-vectored vaccine ConVac expressing SARS-CoV-2 S1 subunit protects hamsters from weight loss and viral replication after SARS-CoV-2 challenge.

bioRxiv · Jan 29, 2021Immunology

mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge

M. Meyer, Y. Wang, D. Edwards, G. R. Smith, A. B. Rubenstein, P. Ramanathan, C. E. Mire, C. Pietzsch, X. Chen, Y. Ge, W. S. Cheng, C. Henry, A. Woods, L. Ma, G. B. E. Stewart-Jones, , A. Bukreyev

This study evaluates mRNA-1273 vaccine efficacy in hamsters, showing reduced pulmonary immune activation and improved disease outcomes after prime-boost vaccination.

bioRxiv · Jan 25, 2021 · PreprintImmunology